Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer

M. A.P. van Ruler, Femke P. Peters, M. Slingerland, M. Fiocco, D. A.R.H. Grootenboers, A. J.E. Vulink, C. A.M. Marijnen, K. J. Neelis

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

12 Citaten (Scopus)


Patients with nonmetastatic esophageal cancer not suitable for surgery can be treated with definitive chemoradiotherapy with curative intent. The purpose of this retrospective study is to evaluate the clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel. Medical records were reviewed of patients treated for nonmetastatic squamous cell or adenocarcinoma of the esophagus between January 2009 and December 2013 in two collaborating institutes. Treatment consisted of external beam radiotherapy (28 fractions of 1.8 Gy) and 6 weekly courses of carboplatin (AUC = 2) and paclitaxel (50 mg/m2). Data on survival, progression, toxicity, and effect on dysphagia were recorded. Sixty-six patients were included. Median overall survival (OS) was 13.1 months (95% CI 4.7-21.5 months) and a 2-year OS was 30% (95% CI 18%-42%). At 2 years, 26% of patients developed local progression (95% CI 15%-37%) and 49% developed distant metastases (95% CI 36%-64%). Acute toxicity grade ≥3 was observed in 47% of patients. Late adverse events grade ≥3 were seen in 20%, mostly esophageal stenoses. Of patients with available data 3 months after treatment, 70% had relief of dysphagia. Definitive chemoradiotherapy led to a median OS of 13 months. Toxicity was common, mostly due to hematological toxicity. Given the relatively short median survival, an adequate selection of patients for this intensive treatment is required.

Originele taal-2Engels
Pagina's (van-tot)1-9
Aantal pagina's9
TijdschriftDiseases of the Esophagus
Nummer van het tijdschrift4
StatusGepubliceerd - 1 apr. 2017
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Clinical outcomes of definitive chemoradiotherapy using carboplatin and paclitaxel in esophageal cancer'. Samen vormen ze een unieke vingerafdruk.

Citeer dit